PET is Wonderful Annual Meeting 2020 Oct 27, 2020 02:00 PM - 05:40 PM — Virtual Meeting (online)
Through the Looking Glass: Breaking Barriers in STEM Oct 28, 2020 12:00 PM - 03:30 PM — Virtual Meeting (online)
NRS Mental Health Network Annual Scientific Meeting 2020 Nov 04, 2020 09:00 AM - 05:30 PM — Virtual Meeting (online)
Scottish Radiological Society Annual General Meeting 2020 Nov 06, 2020 09:30 AM - 03:30 PM — Virtual Meeting (online)
IPEM educational meeting: Artificial Intelligence in MRI Nov 18, 2020 12:00 AM — Virtual Meeting (online)


SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.

Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

EU-funded treatment study: WAKE-UP. A randomized, placebo-controlled MRI-based trial of thrombolysis in wake-up stroke

Author(s): G. Thomalla, M. Ebinger, J. Fiehler, J. B. Fiebach, M. Endres, C. Gerloff

Patients waking up with stroke symptoms are generally excluded from intravenous thrombolysis. It was shown that magnetic resonance imaging (MRI) can identify patients within the time window for thrombolysis (a parts per thousand currency signaEuro parts per thousand 4.5 h from symptom onset) by a mismatch between the acute ischemic lesion visible on diffusion-weighted imaging (DWI) but not visible on fluid-attenuated inversion recovery (FLAIR) imaging. The WAKE-UP trial is an investigator initiated, European, randomized, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based thrombolysis with alteplase (tPA) in stroke patients with unknown time of symptom onset, e.g. due to symptom recognition on awakening. A total of 800 patients showing MRI findings of a DWI-FLAIR-mismatch will be randomized to either tPA or placebo. The primary efficacy endpoint will be favourable outcome defined by a modified Rankin scale score 0-1 at day 90. The primary safety outcome measures will be mortality and death or dependency defined by modified Rankin scale score 4-6 at 90 days. If positive the WAKE-UP trial is expected to change clinical practice and to make effective and safe treatment available for a large group of acute stroke patients currently excluded from specific acute treatment.

Full version: Available here

Click the link to go to an external website with the full version of the paper

ISBN: 0028-2804
Publication Year: 2012
Periodical: Nervenarzt
Periodical Number: 10
Volume: 83
Pages: 1241-+
Author Address: Thomalla, G Univ Klinikum Hamburg Eppendorf, Neurol Klin & Poliklin, Kopf & Neurozentrum, Martinistr 52, D-20246 Hamburg, Germany Univ Klinikum Hamburg Eppendorf, Neurol Klin & Poliklin, Kopf & Neurozentrum, D-20246 Hamburg, Germany Charite, Klin & Hsch Ambulanz Neurol, D-13353 Berlin, Germany Charite, CSB, D-13353 Berlin, Germany Charite, ExzellenzCluster NeuroCure, D-13353 Berlin, Germany Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Neuroradiol Diagnost & Intervent, Diagnost Zentrum, D-20246 Hamburg, Germany